Anika Therapeutics, Inc.ANIKNASDAQ
Loading
Operating Expenses Over TimeStable
Percentile Rank71
3Y CAGR+2.5%
5Y CAGR-5.1%
Year-over-Year Change
Expenses from normal business operations (SG&A, R&D, etc.)
3Y CAGR
+2.5%/yr
vs +7.3%/yr prior
5Y CAGR
-5.1%/yr
Recent acceleration
Acceleration
-4.8pp
Decelerating
Percentile
P71
Within normal range
vs 5Y Ago
0.8x
Contraction
Streak
2 yr
Consecutive declineStable
| Period | Value | YoY Change |
|---|---|---|
| TTM | $74.86M | -7.7% |
| 2024 | $81.10M | -0.7% |
| 2023 | $81.69M | +17.5% |
| 2022 | $69.55M | -13.4% |
| 2021 | $80.33M | -17.5% |
| 2020 | $97.35M | +88.6% |
| 2019 | $51.62M | -1.7% |
| 2018 | $52.53M | +30.3% |
| 2017 | $40.33M | +40.3% |
| 2016 | $28.75M | - |